Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type i Viral Vectors

Thomas J. Conlon, Cathryn S. Mah, Christina A. Pacak, Mary B. Rucker Henninger, Kirsten E. Erger, Marda L. Jorgensen, Charles C Lee, Alice F Tarantal, Barry J. Byrne

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neuromuscular disorders such as Pompe disease (glycogen storage disease, type II), result in early and potentially irreversible cellular damage with a very limited opportunity for intervention in the newborn period. Pompe disease is due to deficiency in acid α-glucosidase (GAA) leading to lysosomal accumulation of glycogen in all cell types, abnormal myofibrillogenesis, respiratory insufficiency, neurological deficits, and reduced contractile function in striated muscle. Previous studies have shown that fetal delivery of recombinant adeno-associated virus (rAAV) encoding GAA to the peritoneal cavity of Gaa-/- mice resulted in high-level transduction of the diaphragm. While progression of other genetic disorders may occur later in life, the potential of fetal gene delivery to avoid the onset of irreversible damage suggests it is an attractive option for many inherited diseases. In this study, rhesus monkey fetuses were administered 4.5 × 1012 particles of rAAV type 1 expressing human GAA (rAAV1-CMV-hGAA), human α-1-antitrypsin (rAAV1-CBA-hAAT), or human mini-dystrophin (rAAV1-CMV-miniDMD) in the late first trimester using an established intraperitoneal ultrasound-guided approach. Fetuses were monitored sonographically and newborns delivered at term for postnatal studies. All animals remained healthy during the study period (growth, hematology, and clinical chemistry), with no evidence of adverse effects. Tissues were collected at a postnatal age of 3 months (~7 months post-fetal gene transfer) for immunohistochemistry (IHC) and quantitative PCR. Both the diaphragm and peritoneum from vector-treated animals were strongly positive for expression of human GAA, AAT, or dystrophin by IHC, similar to findings when reporter genes were used. Protein expression in the diaphragm and peritoneum correlated with high vector copy numbers detected by real-time PCR. Other anatomical areas were negative, although the liver showed minimal evidence of human GAA, AAT, and DMD, vector genomes. In summary, delivery of rAAV vectors provided stable transduction of the muscular component of the diaphragm without any evidence of adverse effects.

Original languageEnglish (US)
Pages (from-to)152-159
Number of pages8
JournalHuman Gene Therapy Clinical Development
Volume27
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Macaca mulatta
Glycogen Storage Disease Type II
Diaphragm
Dependovirus
Dystrophin
Genes
Peritoneum
Fetus
Immunohistochemistry
Glucosidases
Therapeutics
Inborn Genetic Diseases
Clinical Chemistry
Striated Muscle
Muscle Development
Peritoneal Cavity
Hematology
First Pregnancy Trimester
Glycogen
Reporter Genes

Keywords

  • AAV
  • Fetal gene transfer
  • Neuromuscular disorders
  • Pompe disease
  • Rhesus monkey

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)

Cite this

Conlon, T. J., Mah, C. S., Pacak, C. A., Rucker Henninger, M. B., Erger, K. E., Jorgensen, M. L., ... Byrne, B. J. (2016). Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type i Viral Vectors. Human Gene Therapy Clinical Development, 27(4), 152-159. https://doi.org/10.1089/humc.2016.119

Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type i Viral Vectors. / Conlon, Thomas J.; Mah, Cathryn S.; Pacak, Christina A.; Rucker Henninger, Mary B.; Erger, Kirsten E.; Jorgensen, Marda L.; Lee, Charles C; Tarantal, Alice F; Byrne, Barry J.

In: Human Gene Therapy Clinical Development, Vol. 27, No. 4, 01.12.2016, p. 152-159.

Research output: Contribution to journalArticle

Conlon, Thomas J. ; Mah, Cathryn S. ; Pacak, Christina A. ; Rucker Henninger, Mary B. ; Erger, Kirsten E. ; Jorgensen, Marda L. ; Lee, Charles C ; Tarantal, Alice F ; Byrne, Barry J. / Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type i Viral Vectors. In: Human Gene Therapy Clinical Development. 2016 ; Vol. 27, No. 4. pp. 152-159.
@article{78004972ed944cf4ba12e879f60f46cb,
title = "Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type i Viral Vectors",
abstract = "Neuromuscular disorders such as Pompe disease (glycogen storage disease, type II), result in early and potentially irreversible cellular damage with a very limited opportunity for intervention in the newborn period. Pompe disease is due to deficiency in acid α-glucosidase (GAA) leading to lysosomal accumulation of glycogen in all cell types, abnormal myofibrillogenesis, respiratory insufficiency, neurological deficits, and reduced contractile function in striated muscle. Previous studies have shown that fetal delivery of recombinant adeno-associated virus (rAAV) encoding GAA to the peritoneal cavity of Gaa-/- mice resulted in high-level transduction of the diaphragm. While progression of other genetic disorders may occur later in life, the potential of fetal gene delivery to avoid the onset of irreversible damage suggests it is an attractive option for many inherited diseases. In this study, rhesus monkey fetuses were administered 4.5 × 1012 particles of rAAV type 1 expressing human GAA (rAAV1-CMV-hGAA), human α-1-antitrypsin (rAAV1-CBA-hAAT), or human mini-dystrophin (rAAV1-CMV-miniDMD) in the late first trimester using an established intraperitoneal ultrasound-guided approach. Fetuses were monitored sonographically and newborns delivered at term for postnatal studies. All animals remained healthy during the study period (growth, hematology, and clinical chemistry), with no evidence of adverse effects. Tissues were collected at a postnatal age of 3 months (~7 months post-fetal gene transfer) for immunohistochemistry (IHC) and quantitative PCR. Both the diaphragm and peritoneum from vector-treated animals were strongly positive for expression of human GAA, AAT, or dystrophin by IHC, similar to findings when reporter genes were used. Protein expression in the diaphragm and peritoneum correlated with high vector copy numbers detected by real-time PCR. Other anatomical areas were negative, although the liver showed minimal evidence of human GAA, AAT, and DMD, vector genomes. In summary, delivery of rAAV vectors provided stable transduction of the muscular component of the diaphragm without any evidence of adverse effects.",
keywords = "AAV, Fetal gene transfer, Neuromuscular disorders, Pompe disease, Rhesus monkey",
author = "Conlon, {Thomas J.} and Mah, {Cathryn S.} and Pacak, {Christina A.} and {Rucker Henninger}, {Mary B.} and Erger, {Kirsten E.} and Jorgensen, {Marda L.} and Lee, {Charles C} and Tarantal, {Alice F} and Byrne, {Barry J.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1089/humc.2016.119",
language = "English (US)",
volume = "27",
pages = "152--159",
journal = "Human gene therapy. Clinical development",
issn = "2324-8637",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type i Viral Vectors

AU - Conlon, Thomas J.

AU - Mah, Cathryn S.

AU - Pacak, Christina A.

AU - Rucker Henninger, Mary B.

AU - Erger, Kirsten E.

AU - Jorgensen, Marda L.

AU - Lee, Charles C

AU - Tarantal, Alice F

AU - Byrne, Barry J.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Neuromuscular disorders such as Pompe disease (glycogen storage disease, type II), result in early and potentially irreversible cellular damage with a very limited opportunity for intervention in the newborn period. Pompe disease is due to deficiency in acid α-glucosidase (GAA) leading to lysosomal accumulation of glycogen in all cell types, abnormal myofibrillogenesis, respiratory insufficiency, neurological deficits, and reduced contractile function in striated muscle. Previous studies have shown that fetal delivery of recombinant adeno-associated virus (rAAV) encoding GAA to the peritoneal cavity of Gaa-/- mice resulted in high-level transduction of the diaphragm. While progression of other genetic disorders may occur later in life, the potential of fetal gene delivery to avoid the onset of irreversible damage suggests it is an attractive option for many inherited diseases. In this study, rhesus monkey fetuses were administered 4.5 × 1012 particles of rAAV type 1 expressing human GAA (rAAV1-CMV-hGAA), human α-1-antitrypsin (rAAV1-CBA-hAAT), or human mini-dystrophin (rAAV1-CMV-miniDMD) in the late first trimester using an established intraperitoneal ultrasound-guided approach. Fetuses were monitored sonographically and newborns delivered at term for postnatal studies. All animals remained healthy during the study period (growth, hematology, and clinical chemistry), with no evidence of adverse effects. Tissues were collected at a postnatal age of 3 months (~7 months post-fetal gene transfer) for immunohistochemistry (IHC) and quantitative PCR. Both the diaphragm and peritoneum from vector-treated animals were strongly positive for expression of human GAA, AAT, or dystrophin by IHC, similar to findings when reporter genes were used. Protein expression in the diaphragm and peritoneum correlated with high vector copy numbers detected by real-time PCR. Other anatomical areas were negative, although the liver showed minimal evidence of human GAA, AAT, and DMD, vector genomes. In summary, delivery of rAAV vectors provided stable transduction of the muscular component of the diaphragm without any evidence of adverse effects.

AB - Neuromuscular disorders such as Pompe disease (glycogen storage disease, type II), result in early and potentially irreversible cellular damage with a very limited opportunity for intervention in the newborn period. Pompe disease is due to deficiency in acid α-glucosidase (GAA) leading to lysosomal accumulation of glycogen in all cell types, abnormal myofibrillogenesis, respiratory insufficiency, neurological deficits, and reduced contractile function in striated muscle. Previous studies have shown that fetal delivery of recombinant adeno-associated virus (rAAV) encoding GAA to the peritoneal cavity of Gaa-/- mice resulted in high-level transduction of the diaphragm. While progression of other genetic disorders may occur later in life, the potential of fetal gene delivery to avoid the onset of irreversible damage suggests it is an attractive option for many inherited diseases. In this study, rhesus monkey fetuses were administered 4.5 × 1012 particles of rAAV type 1 expressing human GAA (rAAV1-CMV-hGAA), human α-1-antitrypsin (rAAV1-CBA-hAAT), or human mini-dystrophin (rAAV1-CMV-miniDMD) in the late first trimester using an established intraperitoneal ultrasound-guided approach. Fetuses were monitored sonographically and newborns delivered at term for postnatal studies. All animals remained healthy during the study period (growth, hematology, and clinical chemistry), with no evidence of adverse effects. Tissues were collected at a postnatal age of 3 months (~7 months post-fetal gene transfer) for immunohistochemistry (IHC) and quantitative PCR. Both the diaphragm and peritoneum from vector-treated animals were strongly positive for expression of human GAA, AAT, or dystrophin by IHC, similar to findings when reporter genes were used. Protein expression in the diaphragm and peritoneum correlated with high vector copy numbers detected by real-time PCR. Other anatomical areas were negative, although the liver showed minimal evidence of human GAA, AAT, and DMD, vector genomes. In summary, delivery of rAAV vectors provided stable transduction of the muscular component of the diaphragm without any evidence of adverse effects.

KW - AAV

KW - Fetal gene transfer

KW - Neuromuscular disorders

KW - Pompe disease

KW - Rhesus monkey

UR - http://www.scopus.com/inward/record.url?scp=85006790290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006790290&partnerID=8YFLogxK

U2 - 10.1089/humc.2016.119

DO - 10.1089/humc.2016.119

M3 - Article

C2 - 27855487

AN - SCOPUS:85006790290

VL - 27

SP - 152

EP - 159

JO - Human gene therapy. Clinical development

JF - Human gene therapy. Clinical development

SN - 2324-8637

IS - 4

ER -